Transcription of the NKG2D ligand MICA is suppressed by the IRE1/XBP1 pathway of the unfolded protein response through the regulation of E2F1.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 20 11 2018
medline: 13 11 2019
entrez: 20 11 2018
Statut: ppublish

Résumé

The unfolded protein response (UPR) is an adaptive signaling pathway activated in response to endoplasmic reticulum (ER) stress. The effectors of the UPR are potent transcription activators; however, some genes are suppressed by ER stress at the mRNA level. The mechanisms underlying UPR-mediated gene suppression are less known. Exploration of the effect of UPR on NK cells ligand expression found that the transcription of NK group 2 member D (NKG2D) ligand major histocompatibility complex class I polypeptide-related sequence A/B (MICA/B) is suppressed by the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1) pathway of the UPR. Deletion of IRE1 or XBP1 was sufficient to promote mRNA and surface levels of MICA. Accordingly, NKG2D played a greater role in the killing of IRE1/XBP1 knockout target cells. Analysis of effectors downstream to XBP1s identified E2F transcription factor 1 (E2F1) as linking UPR and MICA transcription. The inverse correlation between XBP1 and E2F1 or MICA expression was corroborated in RNA-Seq analysis of 470 primary melanoma tumors. While mechanisms that connect XBP1 to E2F1 are not fully understood, we implicate a few microRNA molecules that are modulated by ER stress and possess dual suppression of E2F1 and MICA. Because of the importance of E2F1 and MICA in cancer progression and recognition, these observations could be exploited for cancer therapy by manipulating the UPR in tumor cells.-Obiedat, A., Seidel, E., Mahameed, M., Berhani, O., Tsukerman, P., Voutetakis, K., Chatziioannou, A., McMahon, M., Avril, T., Chevet, E., Mandelboim, O., Tirosh, B. Transcription of the NKG2D ligand MICA is suppressed by the IRE1/XBP1 pathway of the unfolded protein response through the regulation of E2F1.

Identifiants

pubmed: 30452881
doi: 10.1096/fj.201801350RR
doi:

Substances chimiques

E2F1 Transcription Factor 0
E2F1 protein, human 0
Histocompatibility Antigens Class I 0
KLRK1 protein, human 0
Ligands 0
MHC class I-related chain A 0
NK Cell Lectin-Like Receptor Subfamily K 0
RNA, Messenger 0
Transcription Factors 0
X-Box Binding Protein 1 0
XBP1 protein, human 0
ERN1 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
Endoribonucleases EC 3.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3481-3495

Commentaires et corrections

Type : ErratumIn

Auteurs

Akram Obiedat (A)

Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Einat Seidel (E)

The Lautenberg Center for Immunology and Cancer Research, The Biomedical Research Institute Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem Hadassah Medical School, Jerusalem, Israel.

Mohamed Mahameed (M)

Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Orit Berhani (O)

The Lautenberg Center for Immunology and Cancer Research, The Biomedical Research Institute Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem Hadassah Medical School, Jerusalem, Israel.

Pinchas Tsukerman (P)

The Lautenberg Center for Immunology and Cancer Research, The Biomedical Research Institute Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem Hadassah Medical School, Jerusalem, Israel.

Konstantinos Voutetakis (K)

Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation (NHRF), Athens, Greece.
Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.

Aristotelis Chatziioannou (A)

Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation (NHRF), Athens, Greece.
e-Noesis Inspired Operational Systems Applications Private Company PC, Kallithea-Athens, Greece.

Mari McMahon (M)

INSERM U1242, University of Rennes, Rennes, France.
Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France; and.
Apoptosis Research Centre (ARC), National University of Ireland, Galway (NUIG), Galway, Ireland.

Tony Avril (T)

INSERM U1242, University of Rennes, Rennes, France.
Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France; and.

Eric Chevet (E)

INSERM U1242, University of Rennes, Rennes, France.
Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France; and.

Ofer Mandelboim (O)

The Lautenberg Center for Immunology and Cancer Research, The Biomedical Research Institute Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem Hadassah Medical School, Jerusalem, Israel.

Boaz Tirosh (B)

Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH